Swedish Orphan Biovitrum stock
Price history
+43.35% over the period1 year: from kr 336.80 (November 17, 2025) to kr 482.80 (November 16, 2026), +43.35%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 482.80 |
| October 30, 2026 | kr 490.20 |
| September 30, 2026 | kr 440.40 |
| August 31, 2026 | kr 449.80 |
| July 31, 2026 | kr 470.60 |
| June 30, 2026 | kr 462.00 |
| May 29, 2026 | kr 442.20 |
| April 30, 2026 | kr 427.80 |
| March 31, 2026 | kr 392.20 |
| February 27, 2026 | kr 395.40 |
| January 30, 2026 | kr 337.00 |
| December 30, 2025 | kr 332.80 |
| November 28, 2025 | kr 338.80 |
| November 17, 2025 | kr 336.80 |
At a glance
The company
Biopharma company offering medicines for haematology, immunology and specialty care across Europe, North America, Middle East, Asia and Australia
Latest results
Quarter to September 30, 2026 · EPS kr 6.89 (estimate kr 5.98)
TickerLandia's take on Swedish Orphan Biovitrum
- Priced in line with similar companies: trailing 12-month P/E 25 vs 25 (+1%) in a group of 11.
- Strong point: Growth (76/100 in its group). Weak point: Financial strength (38/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.29% from the 52-week high
Analysts · 12 analysts
Average targetkr 506.50+5.48% vs. price
Buy 6 · Hold 6 · Sell 0 · Buy
TickerLandia Fingerprint: Swedish Orphan Biovitrum
Compared with similar companies: high growth, strong momentum, and high profitability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage58
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 25.0 47 Forward P/E 30.5 74 Price/sales 5.16 75 EV/EBITDA 14.0 40 Price/book 3.63 55 Profitabilityhigh74
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 30.9% 83 ROE 16.3% 68 Gross margin 78.2% 78 Net margin 20.7% 76 ROA 8.1% 65 Earnings stabilityhigh61
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.8% 59 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh76
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +14.54% 80 Earnings growth (year over year) +71.58% 82 Revenue growth (year over year) +17.30% 64 Financial strengthlow38
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.50 53 Current ratio 0.99 9 Interest coverage 10.0 40 Debt/equitycounts in reverse: lower means more financial strength 0.36 49 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong74
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +39.72% 83 Distance from 200-day average +9.18% 66 Risklow30
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 14.6% 14 Volatility (60 days) 26.0% 46
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Swedish Orphan Biovitrum is in line with similar companies
Swedish Orphan Biovitrum's P/E (trailing 12 months): 25.4, in line with the median of a group of 11 similar companies (25.0).
Compared with 11 similar companies
| Metric | Swedish Orphan Biovitrum | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 25.4 | Middle | |
| Forward P/E | 30.9 | High | |
| Operating margin | 30.9% | High | |
| ROE | 16.3% | Middle | |
| Debt/equity | 0.36 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Swedish Orphan Biovitrum. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 9.12B
Latest quarter · Q3 2026
Net income
kr 2.35B
Latest quarter · Q3 2026
Quarterly net margin
25.8%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- kr 167.11B
- P/E
- 25.4
- EPS
- kr 18.94
- Volume
- 435.42K
- Daily trading
- €21.63M
- Dividend yield
- 0.00%
How Swedish Orphan Biovitrum is changing
All resultsRevenue grew 13.1% a year on average over the last 5 years
Operating margin rose from 24.1% to 28.5%
Shares outstanding up 16.8% in 5 years
Returns
Swedish Orphan Biovitrum returns
kr 1,000 invested in Swedish Orphan Biovitrum 5 years ago, on November 16, 2021, would be worth kr 2,218 today: +121.79% in total, +17.27% per year. This is the price return only: dividends are excluded.
| Period | Swedish Orphan Biovitrum | kr 1,000 becomes |
|---|---|---|
| 1 month | +10.63% | kr 1,106 |
| 6 months | +8.89% | kr 1,089 |
| Year to date | +45.07% | kr 1,451 |
| 1 year | +43.35% | kr 1,433 |
| 3 years | +97.06% | kr 1,971 |
| 5 years | +121.79% | kr 2,218 |
| 10 years | +425.43% | kr 5,254 |
Price only, without dividends. Calculate your investment
The chart in detail
Swedish Orphan Biovitrum: technical analysis
Swedish Orphan Biovitrum is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.6% below its all-time closing high (kr 498.20, November 6, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 56
- Between 30 and 70
- vs 200-session average
- +10.39%
Support and resistance
Price areas where Swedish Orphan Biovitrum has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last pricekr 480.20
- Supportkr 472.30−1.65%2 touches, last on August 28, 2026
- Supportkr 448.63−6.57%7 touches, last on September 18, 2026
- Supportkr 433.00−9.83%5 touches, last on September 24, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 25.9%
- Largest fall in the last year
- −14.63%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Swedish Orphan Biovitrum: seasonality
Average monthly price change over 21 years
Over the last 21 years, the strongest month for Swedish Orphan Biovitrum has been January: +5.81% on average, positive in 15 years out of 20. The weakest has been October: −2.31% on average, positive in 8 years out of 21. November, the current month, has been positive in 10 years out of 20 (−1.05% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.81% | +6.77% | 15 of 20 |
| February | +0.90% | +0.89% | 10 of 20 |
| March | +2.56% | +2.07% | 14 of 20 |
| April | +4.79% | +3.03% | 13 of 20 |
| May | +0.21% | −0.67% | 9 of 20 |
| June | +0.27% | +0.64% | 11 of 20 |
| July | +0.63% | −0.80% | 9 of 20 |
| August | +1.64% | +1.88% | 10 of 20 |
| September | +4.14% | +1.09% | 10 of 20 |
| October | −2.31% | −1.30% | 8 of 21 |
| November | −1.05% | −0.19% | 10 of 20 |
| December | +0.22% | −1.80% | 8 of 20 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Swedish Orphan Biovitrum and its competitors
Its medicines are sold across Europe, North America, the Middle East, Asia and Australia. The company works in three segments, Haematology, Immunology and Specialty Care, and its portfolio centres on treatments for haemophilia, such as Alprolix, ALTUVOCT and Elocta/Eloctate, alongside Synagis for respiratory syncytial virus in infants, Kineret for inflammatory conditions including rheumatoid arthritis, and Zynlonta for adult patients with lymphoma. It also markets Doptelet, Gamifant and Orfadin, and develops drug substances for Pfizer's ReFacto AF/Xyntha.
- Headquarters
- Stockholm, Sweden
- Employees
- 2,207
- Founded
- 1939
- Chief executive
- Guido Oelkers
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Swedish Orphan BiovitrumSOBI | $16.63B | 30.9% | 25.4 | +8.89% |
| IpsenIPN | $15.16B | 27.4% | 26.9 | +0.84% |
| H. LundbeckHLUN.A | $8.54B | 24.4% | 14.2 | +62.22% |
| HaleonHLN | $40.03B | 23.5% | 19.2 | +4.15% |
| Sandoz GroupSDZ | $43.66B | 9.3% | 72.3 | +29.20% |
| Galderma GroupGALD | $53.24B | 19.1% | 66.0 | +21.93% |
Same industry or related industries, similar size. Compare Swedish Orphan Biovitrum with its competitors · Full profile
